Upgrade to SI Premium - Free Trial

Genmab A/S (GMAB) PT Raised to $34 at H.C. Wainwright After DARZALEX Combo Results

June 1, 2020 6:59 AM
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Genmab A/S (NASDAQ: GMAB) to $34.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst PT Change

Next Articles